[go: up one dir, main page]

WO2007047372A3 - Traitements pharmacologiques contre des troubles du sommeil - Google Patents

Traitements pharmacologiques contre des troubles du sommeil Download PDF

Info

Publication number
WO2007047372A3
WO2007047372A3 PCT/US2006/039895 US2006039895W WO2007047372A3 WO 2007047372 A3 WO2007047372 A3 WO 2007047372A3 US 2006039895 W US2006039895 W US 2006039895W WO 2007047372 A3 WO2007047372 A3 WO 2007047372A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
combination
prostanoid
prostanoid receptor
apnoe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/039895
Other languages
English (en)
Other versions
WO2007047372A2 (fr
Inventor
David W Carley
Miodrag Radulovacki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois at Urbana Champaign
University of Illinois System
Original Assignee
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana Champaign, University of Illinois System filed Critical University of Illinois at Urbana Champaign
Priority to US12/090,131 priority Critical patent/US8076315B2/en
Publication of WO2007047372A2 publication Critical patent/WO2007047372A2/fr
Publication of WO2007047372A3 publication Critical patent/WO2007047372A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes pour prévenir ou améliorer des troubles de la respiration associés au sommeil. La méthode consiste à administrer à un patient une dose efficace d'un antagoniste ou d'une combinaison d'antagonistes du récepteur prostanoïde. L'antagoniste du récepteur prostanoïde ou la combinaison d'antagonistes du récepteur prostanoïde peuvent être administrés en conjonction avec un ou plusieurs agonistes du récepteur de sérotonine, un ou plusieurs agonistes du récepteur cannabinoïde, un ou plusieurs inhibiteurs de recaptage de sérotonine, un ou plusieurs inhibiteurs de recaptage de noradrénaline, une combinaison d'inhibiteurs de recaptage, un inhibiteur de synthèse de prostanoïde ou une combinaison quelconque de ces substances.
PCT/US2006/039895 2005-10-14 2006-10-13 Traitements pharmacologiques contre des troubles du sommeil Ceased WO2007047372A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/090,131 US8076315B2 (en) 2005-10-14 2006-10-13 Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72690105P 2005-10-14 2005-10-14
US60/726,901 2005-10-14

Publications (2)

Publication Number Publication Date
WO2007047372A2 WO2007047372A2 (fr) 2007-04-26
WO2007047372A3 true WO2007047372A3 (fr) 2007-06-28

Family

ID=37890329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/039895 Ceased WO2007047372A2 (fr) 2005-10-14 2006-10-13 Traitements pharmacologiques contre des troubles du sommeil

Country Status (2)

Country Link
US (1) US8076315B2 (fr)
WO (1) WO2007047372A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503164A (ja) * 2007-11-12 2011-01-27 サムサラ・メディシン・アクチエボラーグ 呼吸障害に関連する方法
CN107630001A (zh) 2008-11-06 2018-01-26 印第安纳大学研究与技术公司 增强造血干细胞植入过程的材料和方法
CA2788284A1 (fr) * 2010-02-09 2011-08-18 Georgia Health Sciences University Research Institute, Inc. Alpha-methyl-tryptophane en tant qu'inhibiteur de l'indole amine dioxygenase
US20120101073A1 (en) * 2010-10-22 2012-04-26 Galleon Pharmaceutical, Inc. Novel Method For Treating Breathing Disorders or Diseases
WO2012061822A2 (fr) * 2010-11-05 2012-05-10 Indiana University Research And Technology Corporation Matériaux et méthodes pour mobiliser des cellules comprenant des cd34+, des cellules formant des colonies hématopoïétiques, et formant des colonies endothéliales
ES2632444T5 (es) 2011-09-30 2022-03-02 Bluebird Bio Inc Compuestos que mejoran la transducción viral
US9381176B2 (en) * 2012-02-24 2016-07-05 Wisconsin Alumni Research Foundation E-prostanoid receptor, Ptger3, as a novel anti-diabetic therapeutic target
WO2014066568A1 (fr) 2012-10-24 2014-05-01 Winthrop-University Hospital Biomarqueur non invasif permettant d'identifier des sujets risquant un accouchement avant terme
CN108883136A (zh) 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
US12234476B2 (en) 2016-02-12 2025-02-25 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
AU2017357747A1 (en) 2016-11-10 2019-05-30 The Research Foundation For The State University Of New York System, method and biomarkers for airway obstruction
CN111094988A (zh) 2017-09-13 2020-05-01 普罗根尼蒂公司 先兆子痫生物标志物及相关系统和方法
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300676A2 (fr) * 1987-07-21 1989-01-25 Merck Frosst Canada Inc. Acides tétrahydrocarbazole-1-alcanoiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7183381B2 (en) * 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300676A2 (fr) * 1987-07-21 1989-01-25 Merck Frosst Canada Inc. Acides tétrahydrocarbazole-1-alcanoiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRIEGER J ET AL: "URINARY EXCRETION OF PROSTANOIDS DURING SLEEP IN OBSTRUCTIVE SLEEP APNOEA PATIENTS", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, XX, XX, vol. 18, no. 8, August 1991 (1991-08-01), pages 551 - 555, XP009081787 *

Also Published As

Publication number Publication date
US8076315B2 (en) 2011-12-13
WO2007047372A2 (fr) 2007-04-26
US20080261922A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
Zupancic et al. Agomelatine: a preliminary review of a new antidepressant
WO2007047372A3 (fr) Traitements pharmacologiques contre des troubles du sommeil
WO2007056300A3 (fr) Procédés et compositions pour le traitement de troubles du système de récompense du cerveau par une thérapie combinée
WO2008040534A3 (fr) Formes pharmaceutiques à base de film non muco-adhésif
NO20080936L (no) Transdermale medikamentleveringsinnretninger inneholdende O-desmetylvenlafaksin (ODV) eller salter derav
Ayatollahi et al. Effect of intravenous vitamin C on postoperative pain in uvulopalatopharyngoplasty with tonsillectomy
IL194885A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an nsaid
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
BR112014007357A2 (pt) métodos de monitoramento terapêutico de fármacos de varredura de nitrogênio
WO2007105113A3 (fr) Application des antagonistes du récepteur crf1 à l'élaboration d'un médicament destiné au traitement du syndrome métabolique et/ou de l'obésité et/ou d'une dyslipoprotéinémie
Habib et al. Transdermal nicotine for analgesia after radical retropubic prostatectomy
JP2005523334A5 (fr)
Elshammaa et al. Ketamine as an adjunct to fentanyl improves postoperative analgesia and hastens discharge in children following tonsillectomy–a prospective, double‐blinded, randomized study
WO2007137204A3 (fr) Méthodes de distribution d'un agoniste bêta2 pour induire une bronchodilatation et formulations utilisées dans ces procédés
CR10801A (es) Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine
Yadav et al. Role of flupirtine as a preemptive analgesic in patients undergoing laparoscopic cholecystectomy
WO2008106689A3 (fr) Gestion de la douleur aiguë
US20140296274A1 (en) Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
Butris et al. Sleep disruption in older surgical patients and its important implications
Prasad et al. A comparative study of pre-operative oral clonidine and pregabalin on post-operative analgesia after spinal anesthesia
WO2008032222A3 (fr) Traitement des vertiges avec de l'acétyl-l-leucine
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
WO2009045900A3 (fr) Méthodes pour traiter ou prévenir des maladies associées à une faible masse osseuse
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12090131

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06825831

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06825831

Country of ref document: EP

Kind code of ref document: A2